Abstract
Peroxisome proliferator-activated receptor gamma (PPARγ) is involved in obesity and in some components of the metabolic syndrome in unselected population. To determine whether PPARγ genetic variants are associated with the risk of developing lipodystrophy and its associated metabolic disturbances in HIV-1-infected patients treated with HAART and to assess PPARγ mRNA expression in subcutaneous adipose tissue (SAT). The study group comprised 278 patients infected with HIV-1 and treated with antiretroviral drugs (139 with lipodystrophy and 139 without) and 105 uninfected controls (UC). The PPARγ Pro12Ala (C > G) single nucleotide polymorphism (SNP) was assessed using PCRRFLPs on white cell DNA. PPARγ mRNA expression in SAT was assessed in 38 patients (25 with lipodystrophy and 13 without) and in 21 UC by real-time PCR. Statistical analysis was based on Students T tests, 2 tests, Spearmans correlations tests and logistic regression tests. PPARγ Pro12Ala genotype distribution and allele frequencies were nonsignificantly different between both HIV-1-infected categories, lipodystrophy vs non-lipodystrophy (p = 0.9 and p = 0.87, respectively). Lipodystrophic patients harbouring the rare X/Ala genotype (Ala/Ala plus Pro/Ala) had significantly greater plasma total and LDL cholesterol levels compared with carriers of the common Pro/Pro genotype (p = 0.029 and p = 0.016, respectively) at univariate analyses. At multivariate analyses these associations were no longer significant. There was a near-significant decreased SAT PPARγ mRNA expression in patients with lipodystrophy compared to UC (p = 0.054). PPARγ Pro12Ala SNP has no effect on the risk of developing lipodystrophy in HIV-1-infected patients treated with HAART. PPARγ mRNA SAT expression appears decreased in lipodystrophy.
Keywords: HIV, Lipodystrophy, dyslipidaemia, PPARγ, Polymorphism, Pharmacogenetics
Current HIV Research
Title: PPARγ Pro12Ala Polymorphism in HIV-1-Infected Patients with HAARTRelated Lipodystrophy
Volume: 7 Issue: 5
Author(s): Consuelo Vilades, Francesc Vidal, Cristobal Richart, Montserrat Olona, Joan Vendrell, Teresa Auguet, Carmen Aguilar, Miguel Lopez-Dupla, Joan-Josep Sirvent, Joaquim Peraire, Maria Saumoy, M Mar Gutierrez, Gerard Aragones, Montserrat Broch, Merce Miranda, Matilde R. Chacon, Pere Domingo, Carlos Alonso-Villaverde and Sergi Veloso
Affiliation:
Keywords: HIV, Lipodystrophy, dyslipidaemia, PPARγ, Polymorphism, Pharmacogenetics
Abstract: Peroxisome proliferator-activated receptor gamma (PPARγ) is involved in obesity and in some components of the metabolic syndrome in unselected population. To determine whether PPARγ genetic variants are associated with the risk of developing lipodystrophy and its associated metabolic disturbances in HIV-1-infected patients treated with HAART and to assess PPARγ mRNA expression in subcutaneous adipose tissue (SAT). The study group comprised 278 patients infected with HIV-1 and treated with antiretroviral drugs (139 with lipodystrophy and 139 without) and 105 uninfected controls (UC). The PPARγ Pro12Ala (C > G) single nucleotide polymorphism (SNP) was assessed using PCRRFLPs on white cell DNA. PPARγ mRNA expression in SAT was assessed in 38 patients (25 with lipodystrophy and 13 without) and in 21 UC by real-time PCR. Statistical analysis was based on Students T tests, 2 tests, Spearmans correlations tests and logistic regression tests. PPARγ Pro12Ala genotype distribution and allele frequencies were nonsignificantly different between both HIV-1-infected categories, lipodystrophy vs non-lipodystrophy (p = 0.9 and p = 0.87, respectively). Lipodystrophic patients harbouring the rare X/Ala genotype (Ala/Ala plus Pro/Ala) had significantly greater plasma total and LDL cholesterol levels compared with carriers of the common Pro/Pro genotype (p = 0.029 and p = 0.016, respectively) at univariate analyses. At multivariate analyses these associations were no longer significant. There was a near-significant decreased SAT PPARγ mRNA expression in patients with lipodystrophy compared to UC (p = 0.054). PPARγ Pro12Ala SNP has no effect on the risk of developing lipodystrophy in HIV-1-infected patients treated with HAART. PPARγ mRNA SAT expression appears decreased in lipodystrophy.
Export Options
About this article
Cite this article as:
Vilades Consuelo, Vidal Francesc, Richart Cristobal, Olona Montserrat, Vendrell Joan, Auguet Teresa, Aguilar Carmen, Lopez-Dupla Miguel, Sirvent Joan-Josep, Peraire Joaquim, Saumoy Maria, Gutierrez Mar M, Aragones Gerard, Broch Montserrat, Miranda Merce, Chacon R. Matilde, Domingo Pere, Alonso-Villaverde Carlos and Veloso Sergi, PPARγ Pro12Ala Polymorphism in HIV-1-Infected Patients with HAARTRelated Lipodystrophy, Current HIV Research 2009; 7 (5) . https://dx.doi.org/10.2174/157016209789346219
DOI https://dx.doi.org/10.2174/157016209789346219 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in people living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Iron Overload is Associated with Perihematoma Edema Growth Following Intracerebral Hemorrhage that may Contribute to In-hospital Mortality and Long-term Functional Outcome
Current Neurovascular Research Enhancement of the Pharmacological Efficacy of FGF-21 by Genetic Modification and PEGylation
Current Pharmaceutical Biotechnology Radiation-Induced Extracranial Carotid Stenosis
Vascular Disease Prevention (Discontinued) Bone Effects of Glitazones and Other Anti-Diabetic Drugs
Current Drug Safety A Review of Dietary Influences on Cardiovascular Health: Part 1: the role of Dietary Nutrients
Cardiovascular & Hematological Disorders-Drug Targets Microvascular Diseases: Is A New Era Coming?
Cardiovascular & Hematological Agents in Medicinal Chemistry A More Accurate Approach to Molecular Genetics Analysis in Vascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Benzimidazole Derivatives as Kinase Inhibitors
Current Medicinal Chemistry Central Nervous System Manifestations in Systemic Lupus Erythematosus
Current Rheumatology Reviews How to Make a Non-Antigenic Protein (Auto) Antigenic: Molecular Complementarity Alters Antigen Processing and Activates Adaptive-Innate Immunity Synergy
Anti-Cancer Agents in Medicinal Chemistry Molecular Basis of Inflammation and Insulin Resistance in Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Effect of Fibrin-binding Synthetic Oligopeptide on the Healing of Full-thickness Skin Wounds in Streptozotocin-induced Diabetic Rats
Current Pharmaceutical Design Homocysteine: A Risk Factor in Patietns with Cardiovascular Disorders in Pakistan
Current Bioactive Compounds The Immunosuppressive Role of Adenosine A2A Receptors in Ischemia Reperfusion Injury and Islet Transplantation
Current Diabetes Reviews Anticoagulant Therapy in Very Old Patients
Cardiovascular & Hematological Disorders-Drug Targets The Therapeutic Role of Renin-Angiotensin System Blockers in Obesity- Related Renal Disorders
Current Clinical Pharmacology The Role of Unbound Drug in Pharmacokinetics/Pharmacodynamics and in Therapy
Current Pharmaceutical Design Metal Induced Conformational Changes in Human Insulin: Crystal Structures of Sr2+, Ni2+ and Cu2+ Complexes of Human Insulin
Protein & Peptide Letters Consequences of Secondary Hyperparathyroidism on Vascular Calcification and Cardiovascular Mortality: Potential Benefit of Calcimimetics
Current Drug Therapy Role of Aberrant Lipid Metabolism of Cancer Stem Cells in Cancer Progression
Current Cancer Drug Targets